Hold Alembic Pharma Ltd For Target Rs. 885 - ICICI Direct
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2021/08/0f98458ee3a98c87b2418413c6cbd583.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
US challenges offset domestic recovery…
About the stock:
Alembic Pharma operates in international generics (54%), domestic branded (28%) and API (18%).
* Exports contribute 69% of sales (US~74%), domestic contributes 31% of sales (Chronic~69% & Acute~31%)
* It has filed 212 ANDA and has 146 approvals with 94 product launches
Q1FY22 Results:
Alembic reported skewed Q1FY22 results.
* Sales declined 1.1% YoY to | 1326 crore
* EBITDA in Q1FY22 was at | 235 crore, down 42% YoY with margins at 17%
* Consequent PAT was at | 164.5 crore (down 45.4% YoY)
What should investors do?
Alembic’s share price has grown by ~1.7x over the past five years (from ~| 573 in June 2016 to ~| 984 levels in June 2021).
* We maintain our HOLD rating on the stock
Target Price and Valuation: We value Alembic at | 885 i.e. 20x P/E on FY23E EPS
Key triggers for future price performance:
* Commercialisation of international formulation plants F2 (Oncology OSD & Injectable), F3 (General Injectable & Ophthalmic) & F4 (new oral solids)
* Maintains aggressive guidance for capex (| 1000 crore for FY22 and FY23) and R&D 12.5-13% of revenues for Fy22
* Expects to launch 15 products in the US in FY22 Consistency of performances in Indian branded formulations
Alternate Stock Idea:
Apart from Alembic, we like Torrent Pharma
* The company’s portfolio is finely balanced between India, Brazil, Germany and the US with India being the leader
* BUY with a target price of | 3290
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Above views are of the author and not of the website kindly read disclaimer
![](https://portfolio.investmentguruindia.com/uploads/news/insurance 123.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Axis Securities Ltd.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Wipro.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/2b1715f7e03b51b0ac9c014eb224fc1f.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/gdp22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dollar retures 2.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/health22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Arvind Kapil, MD and CEO, Poonawalla Fincorp.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/stock8.jpg)
Tag News
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/892c2d00d68c33104f9bb896e2cd4a96.jpg)
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
![Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/22be0ecb7dfcd46b119b708cd51da380.jpg)
![Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/ac1cda4099cf0c445fd6d2081f02ab14.jpg)
![Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/6a3f74c50ac1ab127e5882adbac0bbb8.jpg)